A pharmacokinetic comparison of anrukinzumab, an anti‐ IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients
Fei Hua(Soochow University), Steven W. Martin(Mississippi Delta Community College), Fabio Cataldi(Pfizer (United States)), Jakob Ribbing(Pfizer (United States)), Walter Reinisch(Medical University of Vienna)
Cited by 47
Related Papers
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
|Gastroenterology|2013|938
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
|The Lancet|2023|350
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
|The Lancet|2017|198
Groups IV, V, and X Phospholipases A2s in Human Neutrophils
|Journal of Biological Chemistry|2002|173